Authors: ShihFen Chen YuChih Shen ChiaHsiang Chen
Publish Date: 2009/04/23
Volume: 205, Issue: 2, Pages: 285-292
Abstract
Aripiprazole acts as a partial agonist at dopamine D2 and D3 and serotonin 1A receptors and as an antagonist at serotonin 2A receptors HTR2A Since aripiprazole acts as an antagonist at HTR2A genetic variants of HTR2A may be important in explaining variability in response to aripiprazoleThis study investigated whether the efficacy of aripiprazole can be predicted by functional HTR2A A1438G/T102C polymorphisms rs63311/rs6313 as modified by clinical factors in Han Chinese hospitalized patients with acutely exacerbated schizophreniaAfter hospitalization the patients n = 128 were given a 4week course of aripiprazole Patients were genotyped for HTR2A A1438G/T102C polymorphisms via the restriction fragment length polymorphism method Clinical factors such as gender age duration of illness education level diagnostic subtype and medication dosage were noted as well The researchers measured psychopathology biweekly using the Positive and Negative Syndrome Scale PANSS A mixed model regression approach SAS Proc MIXED was used to analyze the effects of genetic and clinical factors on PANSS performance after aripiprazole treatmentWe found that the GG/CC genotype group of HTR2A A1438G/T102C polymorphisms predicts poor aripiprazole response specifically for negative symptoms In addition the clinical factors including dosage of aripiprazole age duration of illness and diagnostic subtype were found to influence PANSS performance after aripiprazole treatment
Keywords: